Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 7/20 | 0.39 |
| ▸ | TACR1 | P25103 | 3/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | FCER2 | P06734 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | MC3R | P41968 | 1/20 | 0.32 |
| ▸ | MC1R | Q01726 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6317853 | 0.93 | CTSS (0.37) | GHSRTACR1MMP9FCER2MMP8 | |
| SCHEMBL7063301 | 0.84 | GHSR (0.42) | GHSRTACR1FCER2MC4RMC3R | |
| SCHEMBL7063309 | 0.84 | GHSR (0.38) | GHSRTACR1MMP9FCER2MME | |
| SCHEMBL6318989 | 0.78 | GHSR (0.48) | GHSRTACR1MMP9FCER2MMP8 | |
| SCHEMBL7162736 | 0.78 | GHSR (0.48) | GHSRTACR1MMP9FCER2MMP8 | |
| SCHEMBL6318997 | 0.78 | GHSR (0.48) | GHSRTACR1MMP9FCER2MMP8 | |
| SCHEMBL6317857 | 0.77 | CTSB (0.36) | GHSRTACR1MMP9FCER2MMP8 | |
| SCHEMBL6317848 | 0.77 | CTSS (0.40) | GHSRFCER2MC4RMC3RMC1R | |
| SCHEMBL7065310 | 0.77 | GHSR (0.43) | GHSRTACR1 | |
| SCHEMBL7065306 | 0.76 | GHSR (0.42) | GHSRTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, IGFBP1 | GHSR 2/4885TACR1 241/4885MMP9 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.